Quantitative Concept – Page 14

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs

3 months ago talkbio0Tagged Benefit, Financial cost, Health care facility, Hikes, manager, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, specialty generic drugs, United States Federal Trade Commission

FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs

FTC Report Reveals Big 3 PBMs Made $7.3 Billion from Excessive Markups on Specialty Generic Drugs

3 months ago talkbio0Tagged Benefit, Big 3, FTC report, Health care facility, manager, PBMs, Pharmaceutical Services, Prices, specialty generic drugs

FTC report, Big 3 PBMs, Specialty generic drugs, Price markups, Healthcare costs, Pharmacy benefit managers

Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany

3 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Cancer Research, Capacity, Daiichi, Germany, innovation, Manufacturing, Pfaffenhofen facility, Sankyo

Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center

Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding

4 months ago talkbio0Tagged CAR-T, Clearance, Hematologic Neoplasms, in situ, Series, UB-VV111, Umoja Biopharma, United States Food and Drug Administration

Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

4 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

4 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG